Make way for automatic compulsory licencing in pharma: RSS

RSS affiliate Swadeshi Jagran Manch said India should frame policies responsibly

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Press Trust of India New Delhi
Last Updated : Jan 03 2016 | 7:48 PM IST
Lauding India's tough stand on the patents issue, RSS affiliate Swadeshi Jagran Manch (SJM) today asked the government not to give in to US pressure and urged it to make provisions for liberal and automatic compulsory licencing of pharma products.

Noting that India is known as the 'Pharmacy of the World' for providing cheap medicines for those affected by blood cancer, HIV-AIDS and other serious diseases, SJM said it should frame policies responsibly.

"We demand that there should be a liberal provision for granting automatic compulsory licence for other pharma products provided that a domestic producer is ready to produce and supply at one-fourth of the price of the patented product, giving reasonable royalty to the patent holder," SJM co-convener Ashwani Mahajan told PTI.

He said that due to its responsibility towards humanity, "the government has rightfully dismissed the (Barack) Obama administration's pressure completely and has clearly refused to give in". It further alleged that the previous government, however, "could not gather courage" in this regard.

"SJM welcomes the central government's decision to not relax provisions related to the issue of compulsory licensing and Section 3(d) of the Patent Act relating to not granting re-patent of pharma products, dismissing the pressure from the US government and pharma lobby.

"The Manch urges the central government that when it frames rules in this regard, it should continue with the same forthrightness and make no compromises. There are many patented, costly life-saving medicines and the Manch urges the government to be liberal in its policy of automatic and compulsory licensing," he said.

Mahajan said that the government has been sensitive to the rising cost of healthcare and 40 per cent of the patients are able to get treatment for such ailments as blood cancer, HIV-AIDS and other serious diseases only due to the cheap medicines provided by India.

So far, only one compulsory licence has been issued to NATCO and the Manch said that the NDA government should issue more such licences to pharma units to help ensure cheaper medicines and healthcare in the country.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 03 2016 | 6:32 PM IST

Next Story